Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

• Published in: Vaccine Vol. 41; no. 41; pp. 5965 - 5973
• Main Authors: Raiser, Fritz, Davis, Matthew, Adelglass, Jeffrey, Cai, Miranda R., Chau, Gordon, Cloney-Clark, Shane, Eickhoff, Mark, Kalkeri, Raj, McKnight, Irene, Plested, Joyce, Zhu, Mingzhu, Dunkle, Lisa M.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 22.09.2023; Elsevier Limited
• Subjects: Adults; Booster; Clinical trials; COVID-19; COVID-19 vaccines; Disease transmission; FDA approval; IgG antibody; Immunogenicity; Immunoglobulin G; Manufacturing; mRNA; mRNA vaccines; Myocarditis; NVX-CoV2373; Pandemics; Pericarditis; Proteins; Public health; Robustness; Safety; SARS-CoV-2 variants; Seroconversion; Severe acute respiratory syndrome coronavirus 2; Vaccines; United States > US; mRNA vaccines; SARS-CoV-2 variants; Immunogenicity; NVX-CoV2373; Booster

•NVX-CoV2373 manufacturing lots are consistently immunogenic and well-tolerated.•NVX-CoV2373 can be used as a first booster dose or a later booster dose.•NVX-CoV2373 is also immunogenic against Omicron BA.1/BA.5 SARS-CoV-2 variants. To combat the SARS-CoV-2 pandemic, multiple vaccines using differen...